Trimetazidine

  • Email
  • Help

On 21 June 2012, the European Medicines Agency completed a review of the safety and effectiveness of trimetazidine following concerns over its effectiveness and reports of movement disorders such as Parkinsonian symptoms with these medicines. The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits continue to outweigh the risks in patients with angina pectoris but that treatment should be restricted to add-on to existing treatments in patients who are not adequately controlled by or who are intolerant to other medicines for angina pectoris. For the symptomatic treatment of tinnitus, vertigo and visual-field disturbances, the CHMP concluded that the benefits no longer outweigh the risks and that these uses should no longer be authorised. In addition, the Committee recommended new contraindications and warnings to reduce and manage the possible risk of movement disorders, associated with the use of this medicine.

What is trimetazidine?

Trimetazidine is a medicine used to prevent angina attacks, which are sudden pains to the chest, jaw and back brought on by physical effort, due to reduced blood flow to the heart. Angina is commonly associated with a narrowing of the blood vessels that supply the heart, called the coronary arteries.

Trimetazidine is a ‘metabolic agent’, a medicine which has an effect on metabolism (the process by which substances are broken down in the body). It is believed to protect against myocardial ischaemia (reduced blood supply to the heart muscle) by increasing the rate at which glucose is broken down.

Trimetazidine is also used to treat the symptoms of vertigo (a spinning sensation) and tinnitus (ringing sensation in the ears), and to treat reduced vision and visual field disturbances (unclear or disturbed vision) due to problems affecting the blood vessels.

Medicines containing trimetazidine have been available since the 1970s and are currently marketed in Bulgaria, Cyprus, the Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia, Slovenia and Spain. They are marketed under the invented name Vastarel and other trade names.

Why was trimetazidine reviewed?

In April 2011, the French medicines regulatory agency concluded that, based on a review of the evidence in France, the risks of medicines containing trimetazidine were greater than the benefits for all the authorised indications. A main concern was that the effectiveness of trimetazidine had not been convincingly demonstrated in any of the authorised indications, since the studies supporting the authorised uses had several methodological weaknesses and only showed a small benefit. 

In addition, there were concerns regarding the safety of trimetazidine-containing medicines following reports of Parkinson syndrome (a group of symptoms that include shaking, slow movement and muscle stiffness) and other motor disorders such as tremor (shaking), muscle rigidity and walking disorders, and restless-legs syndrome (a disorder where the patient has uncontrollable urges to move the limbs to stop uncomfortable, painful or odd sensations in the body, usually at night). These symptoms were seen in some patients with no previous history of Parkinson syndrome, and in many cases their symptoms resolved when they stopped taking trimetazidine. 

Despite strengthening the warnings in the prescribing information of these medicines, the French agency remained concerned that the benefits for trimetazidine did not outweigh its risks. Consequently, on 22 April 2011 it asked the CHMP to issue an opinion on the benefit-risk balance of trimetzidine-containing medicines, and on whether the marketing authorisation for these medicines should be maintained, varied, suspended or withdrawn across the EU.

Which data has the CHMP reviewed?

The CHMP looked at data from clinical studies, the published literature, spontaneous reports of side effects and data submitted by the companies that market medicines containing trimetazidine.

What are the conclusions of the CHMP?

Regarding the use of trimetazidine in angina pectoris, the Committee noted that the studies carried out to show its effects had some limitations and were often of short duration. Although the studies did not show that the benefits outweighed the risks for trimetazidine when used alone as first-line treatment, the studies supported the use of trimetazidine as add-on to existing treatments in patients who are not adequately controlled by or intolerant to other medicines for angina pectoris. To address the lack of long-term data on trimetazidine, a study investigating the long-term effects of trimetazidine will be carried out. 

Regarding the use of trimetazidine in tinnitus, vertigo and visual-field disturbances, the studies had poor methodology and did not demonstrate a clinical benefit of trimetazidine when compared with placebo (a dummy treatment) or alternative medicines. In addition, the CHMP noted that trimetazidine is often used to treat these conditions in older patients for longer and at higher doses than recommended, increasing the risk of side effects such as falls, which undermines the use of trimetazidine for these conditions. 

An analysis of relevant safety data showed that movement disorders, including Parkinsonism, cannot be excluded with trimetazidine, although these are not common and are reversible after discontinuing trimetazidine. The CHMP therefore recommended that a warning should be included in the product information on trimetazidine-induced Parkinsonism, its diagnosis and management. It also recommended contraindicating trimetazidine in patients with Parkinson disease or Parkinsonian symptoms and in patients with severely reduced kidney function. 

Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of trimetazidine continue to outweigh its risks when used as add-on treatment in patients with angina pectoris, but that changes should be made to the product information to ensure the safe use of these medicines. For use in tinnitus, vertigo and visual-field disturbances, the benefits no longer outweigh the risks and the CHMP recommended that these uses should no longer be authorised. Written communication will be distributed to doctors at national level to inform them of the changes to the approved uses of trimetazidine.

What are the recommendations for patients?
  • There is no need for an urgent change in treatment, but doctors will review their patients’ treatment at their next routine appointment.
  • Patients currently receiving trimetazidine for tinnitus, vertigo and disturbances in vision should consult their doctor so they can switch to an appropriate alternative treatment.
  • Patients currently receiving trimetazidine for angina pectoris should consult their doctor to ensure that it is the most appropriate treatment for their condition or to arrange alternative treatment if necessary.
  • Patients who have any questions should speak to their doctor or pharmacist.
What are the recommendations for prescribers?
  • There is no need for an urgent change in treatment, but doctors should review their patients’ treatment at their next routine appointment.
  • Prescribers should no longer prescribe trimetazidine for treating tinnitus, vertigo and disturbances in vision and switch patients to appropriate alternative treatment.
  • Trimetazidine should only be used in the symptomatic treatment of angina pectoris, and only as add-on to existing treatments in patients who are not adequately controlled by or who are intolerant to other medicines for angina pectoris.
  • Prescribers must not prescribe trimetazidine in patients with Parkinson disease or Parkinsonian symptoms and in patients with severely reduced kidney function. For patients with moderately reduced kidney failure and elderly patients, the dose should be reduced.
  • Trimetazidine should be discontinued permanently in patients who develop movement disorders such as Parkinsonian symptoms. If Parkinsonian symptoms persist for more than four months after discontinuation, a neurologist’s opinion should be sought.

The European Commission issued a decision on this opinion on 3 September 2012.

Name Language First published Last updated
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) BG = bălgarski 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) ES = español 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) CS = čeština 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) DA = dansk 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) DE = Deutsch 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) ET = eesti keel 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) EL = elliniká 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) EN = English 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) FR = français 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) IT = italiano 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) LV = latviešu valoda 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) LT = lietuvių kalba 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) HU = magyar 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) MT = Malti 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) NL = Nederlands 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) PL = polski 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) PT = português 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) RO = română 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) SK = slovenčina 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) SL = slovenščina 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) FI = suomi 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) SV = svenska 22/06/2012 17/10/2012

Key facts

Approved nameTrimetazidine
International non-proprietary name (INN) or common name

Trimetazidine

Associated namesVastravel
Class
Reference numberEMEA/H/A-31/1305
TypeArticle 31 referrals

This type of referral is triggered when the interest of the Community is involved, following concerns relating to the quality, safety or efficacy of a medicine or a class of medicines.

StatusEuropean Commission final decision
Opinion date21/06/2012

All documents

Name Language First published Last updated
Trimetazidine - Article 31 referral - Assessment report (English only) 17/10/2012  
Trimetazidine - Article 31 - Annex I BG = bălgarski 17/10/2012  
Trimetazidine - Article 31 - Annex I ES = español 17/10/2012  
Trimetazidine - Article 31 - Annex I CS = čeština 17/10/2012  
Trimetazidine - Article 31 - Annex I DA = dansk 17/10/2012  
Trimetazidine - Article 31 - Annex I DE = Deutsch 17/10/2012  
Trimetazidine - Article 31 - Annex I ET = eesti keel 17/10/2012  
Trimetazidine - Article 31 - Annex I EL = elliniká 17/10/2012  
Trimetazidine - Article 31 - Annex I EN = English 17/10/2012  
Trimetazidine - Article 31 - Annex I FR = français 17/10/2012  
Trimetazidine - Article 31 - Annex I IT = italiano 17/10/2012  
Trimetazidine - Article 31 - Annex I LV = latviešu valoda 17/10/2012  
Trimetazidine - Article 31 - Annex I LT = lietuvių kalba 17/10/2012  
Trimetazidine - Article 31 - Annex I HU = magyar 17/10/2012  
Trimetazidine - Article 31 - Annex I MT = Malti 17/10/2012  
Trimetazidine - Article 31 - Annex I NL = Nederlands 17/10/2012  
Trimetazidine - Article 31 - Annex I PL = polski 17/10/2012  
Trimetazidine - Article 31 - Annex I PT = português 17/10/2012  
Trimetazidine - Article 31 - Annex I RO = română 17/10/2012  
Trimetazidine - Article 31 - Annex I SK = slovenčina 17/10/2012  
Trimetazidine - Article 31 - Annex I SL = slovenščina 17/10/2012  
Trimetazidine - Article 31 - Annex I FI = suomi 17/10/2012  
Trimetazidine - Article 31 - Annex I SV = svenska 17/10/2012  
Trimetazidine - Article 31 - Annex II BG = bălgarski 17/10/2012  
Trimetazidine - Article 31 - Annex II ES = español 17/10/2012  
Trimetazidine - Article 31 - Annex II CS = čeština 17/10/2012  
Trimetazidine - Article 31 - Annex II DA = dansk 17/10/2012  
Trimetazidine - Article 31 - Annex II DE = Deutsch 17/10/2012  
Trimetazidine - Article 31 - Annex II ET = eesti keel 17/10/2012  
Trimetazidine - Article 31 - Annex II EL = elliniká 17/10/2012  
Trimetazidine - Article 31 - Annex II EN = English 17/10/2012  
Trimetazidine - Article 31 - Annex II FR = français 17/10/2012  
Trimetazidine - Article 31 - Annex II IT = italiano 17/10/2012  
Trimetazidine - Article 31 - Annex II LV = latviešu valoda 17/10/2012  
Trimetazidine - Article 31 - Annex II LT = lietuvių kalba 17/10/2012  
Trimetazidine - Article 31 - Annex II HU = magyar 17/10/2012  
Trimetazidine - Article 31 - Annex II MT = Malti 17/10/2012  
Trimetazidine - Article 31 - Annex II NL = Nederlands 17/10/2012  
Trimetazidine - Article 31 - Annex II PL = polski 17/10/2012  
Trimetazidine - Article 31 - Annex II PT = português 17/10/2012  
Trimetazidine - Article 31 - Annex II RO = română 17/10/2012  
Trimetazidine - Article 31 - Annex II SK = slovenčina 17/10/2012  
Trimetazidine - Article 31 - Annex II SL = slovenščina 17/10/2012  
Trimetazidine - Article 31 - Annex II FI = suomi 17/10/2012  
Trimetazidine - Article 31 - Annex II SV = svenska 17/10/2012  
Trimetazidine - Article 31 - Annex III BG = bălgarski 17/10/2012  
Trimetazidine - Article 31 - Annex III ES = español 17/10/2012  
Trimetazidine - Article 31 - Annex III CS = čeština 17/10/2012  
Trimetazidine - Article 31 - Annex III DA = dansk 17/10/2012  
Trimetazidine - Article 31 - Annex III DE = Deutsch 17/10/2012  
Trimetazidine - Article 31 - Annex III ET = eesti keel 17/10/2012  
Trimetazidine - Article 31 - Annex III EL = elliniká 17/10/2012  
Trimetazidine - Article 31 - Annex III EN = English 17/10/2012  
Trimetazidine - Article 31 - Annex III FR = français 17/10/2012  
Trimetazidine - Article 31 - Annex III IT = italiano 17/10/2012  
Trimetazidine - Article 31 - Annex III LV = latviešu valoda 17/10/2012  
Trimetazidine - Article 31 - Annex III LT = lietuvių kalba 17/10/2012  
Trimetazidine - Article 31 - Annex III HU = magyar 17/10/2012  
Trimetazidine - Article 31 - Annex III MT = Malti 17/10/2012  
Trimetazidine - Article 31 - Annex III NL = Nederlands 17/10/2012  
Trimetazidine - Article 31 - Annex III PL = polski 17/10/2012  
Trimetazidine - Article 31 - Annex III PT = português 17/10/2012  
Trimetazidine - Article 31 - Annex III RO = română 17/10/2012  
Trimetazidine - Article 31 - Annex III SK = slovenčina 17/10/2012  
Trimetazidine - Article 31 - Annex III SL = slovenščina 17/10/2012  
Trimetazidine - Article 31 - Annex III FI = suomi 17/10/2012  
Trimetazidine - Article 31 - Annex III SV = svenska 17/10/2012  
Trimetazidine - Article 31 - Annex IV BG = bălgarski 17/10/2012  
Trimetazidine - Article 31 - Annex IV ES = español 17/10/2012  
Trimetazidine - Article 31 - Annex IV CS = čeština 17/10/2012  
Trimetazidine - Article 31 - Annex IV DA = dansk 17/10/2012  
Trimetazidine - Article 31 - Annex IV DE = Deutsch 17/10/2012  
Trimetazidine - Article 31 - Annex IV ET = eesti keel 17/10/2012  
Trimetazidine - Article 31 - Annex IV EL = elliniká 17/10/2012  
Trimetazidine - Article 31 - Annex IV EN = English 17/10/2012  
Trimetazidine - Article 31 - Annex IV FR = français 17/10/2012  
Trimetazidine - Article 31 - Annex IV IT = italiano 17/10/2012  
Trimetazidine - Article 31 - Annex IV LV = latviešu valoda 17/10/2012  
Trimetazidine - Article 31 - Annex IV LT = lietuvių kalba 17/10/2012  
Trimetazidine - Article 31 - Annex IV HU = magyar 17/10/2012  
Trimetazidine - Article 31 - Annex IV MT = Malti 17/10/2012  
Trimetazidine - Article 31 - Annex IV NL = Nederlands 17/10/2012  
Trimetazidine - Article 31 - Annex IV PL = polski 17/10/2012  
Trimetazidine - Article 31 - Annex IV PT = português 17/10/2012  
Trimetazidine - Article 31 - Annex IV RO = română 17/10/2012  
Trimetazidine - Article 31 - Annex IV SK = slovenčina 17/10/2012  
Trimetazidine - Article 31 - Annex IV SL = slovenščina 17/10/2012  
Trimetazidine - Article 31 - Annex IV FI = suomi 17/10/2012  
Trimetazidine - Article 31 - Annex IV SV = svenska 17/10/2012  
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) BG = bălgarski 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) ES = español 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) CS = čeština 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) DA = dansk 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) DE = Deutsch 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) ET = eesti keel 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) EL = elliniká 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) EN = English 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) FR = français 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) IT = italiano 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) LV = latviešu valoda 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) LT = lietuvių kalba 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) HU = magyar 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) MT = Malti 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) NL = Nederlands 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) PL = polski 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) PT = português 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) RO = română 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) SK = slovenčina 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) SL = slovenščina 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) FI = suomi 22/06/2012 17/10/2012
Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) SV = svenska 22/06/2012 17/10/2012

Document description

  • Questions and answers (Q&A) - easy-to-understand summary of key issues and Committee conclusions
  • Summary of Opinion - contains the CHMP opinion of the referred medicine(s)
  • List of the medicines affected by the referral (Annex I)
  • Scientific conclusions of the Committee (Annex II)

The following two documents are sometimes available:

  • Changes to the summary of product characteristics, labeling or package leaflet (also known as Annex III) - available when changes have been recommended by the Committee
  • Conditions of the marketing authorisation (also known as Annex IV) - available when the Committee recommends measures to be taken for the marketing authorisation(s) such as safety measures or extra studies

Current status:
European Commission final decision

Related information